Spotlight on our Phase 3 programs . ABC: antibody biopolymer conjugate; DR: diabetic retinopathy; RVO: retinal vein occlusion; AMD: age-related macular degeneration Quadrant of core unmet need Quadrant of core unmet need Greenfield market opportunity 5 • Strong immediacy • Industry leading durability • BLA filing expected 2026 in 3 indications of wet AMD, DR and RVO Tarcocimab Anti-VEGF ABC ® biologic designed for: KSI-501 Anti-IL-6, VEGF trap bispecific ABC ® biologic designed for: • High-strength, dual inhibition of IL-6 and VEGF • Safe and potent control of macular edema secondary to inflammation (MESI) KSI-101 Anti-IL-6, VEGF trap bispecific protein designed for: For patients with retinal vascular diseases For patients with MESI • Improved efficacy beyond anti-VEGF monotherapies • Strong immediacy • Industry leading durability